33% REVENUE GROWTH WITH NAMED PATIENT PROGRAM
U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication.
Forecast in the U.S. was ~ 500 patients.
Challenged to increase revenue potential for the brand.
Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets.
Identified & vetted a vendor with EU & ROW capabilities.
Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs.
By end of year 1, 1/3 of all product sales occurring outside of U.S.
Distribution eventually expanded to multiple markets, including EU, Asia, & South America.
All NPP sales counted toward U.S. revenue (top line).
Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was approved in ex-U.S. markets.